Intuitive Surgical Inc（ISRG）の株式分析ISRGIntuitive Surgical Inc

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Intuitive Surgical Inc (ISRG) is currently at a price of $372.60, which is significantly lower than the analyst price target of $500 set by Oppenheimer. However, the stock has a low RSI of 41.97, indicating it is nearing oversold territory. The company faces strong competition, which is a risk, as evidenced by the recent downgrade from HSBC, which set a lower target of $391. Given the mixed signals from analysts and the current market pressures, it is advisable to hold rather than buy at this time.

17 analysts cover ISRG: 11 rate it Buy, 5 Hold and 1 Sell. The average price target is 637.32.